메뉴 건너뛰기




Volumn 245, Issue , 2017, Pages 95-107

Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges

Author keywords

Alzheimer's disease; Clinical trials; Industrial perspectives; Nanocarriers; Nanoparticles; Nanotechnology

Indexed keywords

CLINICAL RESEARCH; CONTROLLED DRUG DELIVERY; DEVELOPING COUNTRIES; DIAGNOSIS; DRUG DOSAGE; DRUG INTERACTIONS; NANOPARTICLES; NANOTECHNOLOGY; TARGETED DRUG DELIVERY;

EID: 84998636564     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.11.025     Document Type: Review
Times cited : (180)

References (117)
  • 1
    • 84969664011 scopus 로고    scopus 로고
    • Alzheimer's disease: potential preventive, non-invasive, intervention strategies in lowering the risk of cognitive decline — a review study
    • [1] Klimova, B., Kuca, K., Alzheimer's disease: potential preventive, non-invasive, intervention strategies in lowering the risk of cognitive decline — a review study. J. Appl. Biomed. 13:4 (2015), 257–261.
    • (2015) J. Appl. Biomed. , vol.13 , Issue.4 , pp. 257-261
    • Klimova, B.1    Kuca, K.2
  • 2
    • 84925880097 scopus 로고    scopus 로고
    • 2015 — Alzheimer's disease facts and figures
    • [2] Alzheimer's, A., 2015 — Alzheimer's disease facts and figures. Alzheimer's Dementia, 11(3), 2015, 332.
    • (2015) Alzheimer's Dementia , vol.11 , Issue.3 , pp. 332
    • Alzheimer's, A.1
  • 3
    • 79956098248 scopus 로고    scopus 로고
    • Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    • [3] Sperling, R.A., Aisen, P.S., Beckett, L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dementia 7:3 (2011), 280–292.
    • (2011) Alzheimer's Dementia , vol.7 , Issue.3 , pp. 280-292
    • Sperling, R.A.1    Aisen, P.S.2    Beckett, L.A.3
  • 4
    • 84875250937 scopus 로고    scopus 로고
    • Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
    • [4] Villemagne, V.L., Burnham, S., Bourgeat, P., et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12:4 (2013), 357–367.
    • (2013) Lancet Neurol. , vol.12 , Issue.4 , pp. 357-367
    • Villemagne, V.L.1    Burnham, S.2    Bourgeat, P.3
  • 5
    • 84869126018 scopus 로고    scopus 로고
    • Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study
    • [5] Reiman, E.M., Quiroz, Y.T., Fleisher, A.S., et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 11:12 (2012), 1048–1056.
    • (2012) Lancet Neurol. , vol.11 , Issue.12 , pp. 1048-1056
    • Reiman, E.M.1    Quiroz, Y.T.2    Fleisher, A.S.3
  • 7
    • 84876891556 scopus 로고    scopus 로고
    • Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease
    • [7] Gauthier, S., Molinuevo, J.L., Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease. Alzheimer's Dementia 9:3 (2013), 326–331.
    • (2013) Alzheimer's Dementia , vol.9 , Issue.3 , pp. 326-331
    • Gauthier, S.1    Molinuevo, J.L.2
  • 8
    • 3042833662 scopus 로고    scopus 로고
    • Alzheimer's disease pathogenesis and therapeutic interventions
    • [8] Parihar, M., Hemnani, T., Alzheimer's disease pathogenesis and therapeutic interventions. J. Clin. Neurosci. 11:5 (2004), 456–467.
    • (2004) J. Clin. Neurosci. , vol.11 , Issue.5 , pp. 456-467
    • Parihar, M.1    Hemnani, T.2
  • 9
    • 67651180986 scopus 로고    scopus 로고
    • The amyloid hypothesis for Alzheimer's disease: a critical reappraisal
    • [9] Hardy, J., The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem. 110:4 (2009), 1129–1134.
    • (2009) J. Neurochem. , vol.110 , Issue.4 , pp. 1129-1134
    • Hardy, J.1
  • 10
    • 79959886270 scopus 로고    scopus 로고
    • Amyloid precursor protein processing and Alzheimer's disease
    • [10] O'Brien, R.J., Wong, P.C., Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 34 (2011), 185–204.
    • (2011) Annu. Rev. Neurosci. , vol.34 , pp. 185-204
    • O'Brien, R.J.1    Wong, P.C.2
  • 11
    • 0004681572 scopus 로고
    • Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloidogenic derivative
    • [11] Glenner, G., Wong, C., Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloidogenic derivative. Science 255 (1984), 728–730.
    • (1984) Science , vol.255 , pp. 728-730
    • Glenner, G.1    Wong, C.2
  • 12
    • 77953518555 scopus 로고    scopus 로고
    • Alzheimer's disease: clinical trials and drug development
    • [12] Mangialasche, F., Solomon, A., Winblad, B., et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9:7 (2010), 702–716.
    • (2010) Lancet Neurol. , vol.9 , Issue.7 , pp. 702-716
    • Mangialasche, F.1    Solomon, A.2    Winblad, B.3
  • 13
    • 79955738773 scopus 로고    scopus 로고
    • The history of the cholinergic hypothesis
    • [13] Contestabile, A., The history of the cholinergic hypothesis. Behav. Brain Res. 221:2 (2011), 334–340.
    • (2011) Behav. Brain Res. , vol.221 , Issue.2 , pp. 334-340
    • Contestabile, A.1
  • 14
    • 65249104851 scopus 로고    scopus 로고
    • Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases
    • [14] Dong, X.-X., Wang, Y., Z-H, Q., Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 30:4 (2009), 379–387.
    • (2009) Acta Pharmacol. Sin. , vol.30 , Issue.4 , pp. 379-387
    • Dong, X.-X.1    Wang, Y.2    Z-H, Q.3
  • 15
    • 19944375450 scopus 로고    scopus 로고
    • Tau pathology in Alzheimer disease and other tauopathies
    • [15] Iqbal, K., Alonso, A.C., Chen, S., et al. Tau pathology in Alzheimer disease and other tauopathies. BBA-Mol. Basis Dis. 1739:2 (2005), 198–210.
    • (2005) BBA-Mol. Basis Dis. , vol.1739 , Issue.2 , pp. 198-210
    • Iqbal, K.1    Alonso, A.C.2    Chen, S.3
  • 16
    • 84867608068 scopus 로고    scopus 로고
    • Tau protein kinases: involvement in Alzheimer's disease
    • [16] Martin, L., Latypova, X., Wilson, C.M., et al. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res. Rev. 12:1 (2013), 289–309.
    • (2013) Ageing Res. Rev. , vol.12 , Issue.1 , pp. 289-309
    • Martin, L.1    Latypova, X.2    Wilson, C.M.3
  • 17
    • 84903304968 scopus 로고    scopus 로고
    • The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives
    • [17] Swerdlow, R.H., Burns, J.M., Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim. Biophys. Acta Mol. basis Dis. 1842:8 (2014), 1219–1231.
    • (2014) Biochim. Biophys. Acta Mol. basis Dis. , vol.1842 , Issue.8 , pp. 1219-1231
    • Swerdlow, R.H.1    Burns, J.M.2    Khan, S.M.3
  • 19
    • 84918504163 scopus 로고    scopus 로고
    • Central nervous system stimulants and drugs that suppress appetite
    • D.R. Sidhartha Elsevier
    • [19] Aagaard, L., Central nervous system stimulants and drugs that suppress appetite. Sidhartha, D.R., (eds.) Side Effects of Drugs Annual, 2014, Elsevier, 1–9.
    • (2014) Side Effects of Drugs Annual , pp. 1-9
    • Aagaard, L.1
  • 20
    • 56949084877 scopus 로고    scopus 로고
    • Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles
    • [20] Kratz, F., Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132:3 (2008), 171–183.
    • (2008) J. Control. Release , vol.132 , Issue.3 , pp. 171-183
    • Kratz, F.1
  • 21
    • 84961216466 scopus 로고    scopus 로고
    • Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management
    • [21] Hanafy, A.S., Farid, R.M., Helmy, M.W., et al. Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management. Drug Deliv., 1–12, 2016.
    • (2016) Drug Deliv. , vol.1-12
    • Hanafy, A.S.1    Farid, R.M.2    Helmy, M.W.3
  • 22
    • 84961618744 scopus 로고    scopus 로고
    • The “fate” of polymeric and lipid nanoparticles for brain delivery and targeting: strategies and mechanism of blood–brain barrier crossing and trafficking into the central nervous system
    • [22] Tosi, G., Musumeci, T., Ruozi, B., et al. The “fate” of polymeric and lipid nanoparticles for brain delivery and targeting: strategies and mechanism of blood–brain barrier crossing and trafficking into the central nervous system. J. Drug Delivery Sci. Technol. 32 (2016), 66–76.
    • (2016) J. Drug Delivery Sci. Technol. , vol.32 , pp. 66-76
    • Tosi, G.1    Musumeci, T.2    Ruozi, B.3
  • 23
    • 84927686841 scopus 로고    scopus 로고
    • Nanoparticles for diagnosis and/or treatment of Alzheimer's disease
    • [23] Antimisiaris, S., Mourtas, S., Markoutsa, E., et al. Nanoparticles for diagnosis and/or treatment of Alzheimer's disease. Adv. Healthc. Mater., 87–179, 2014.
    • (2014) Adv. Healthc. Mater. , vol.87-179
    • Antimisiaris, S.1    Mourtas, S.2    Markoutsa, E.3
  • 24
    • 84859958800 scopus 로고    scopus 로고
    • Nanotechnological advances for the delivery of CNS therapeutics
    • [24] Wong, H.L., Wu, X.Y., Bendayan, R., Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev. 64:7 (2012), 686–700.
    • (2012) Adv. Drug Deliv. Rev. , vol.64 , Issue.7 , pp. 686-700
    • Wong, H.L.1    Wu, X.Y.2    Bendayan, R.3
  • 25
    • 84890941075 scopus 로고    scopus 로고
    • Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and Schizophrenia
    • [25] Silva, A., González-Mira, E., Lobo, J.S., et al. Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and Schizophrenia. Curr. Pharm. Des. 19:41 (2013), 7185–7195.
    • (2013) Curr. Pharm. Des. , vol.19 , Issue.41 , pp. 7185-7195
    • Silva, A.1    González-Mira, E.2    Lobo, J.S.3
  • 26
    • 84873046533 scopus 로고    scopus 로고
    • Biocompatibility of engineered nanoparticles for drug delivery
    • [26] Naahidi, S., Jafari, M., Edalat, F., et al. Biocompatibility of engineered nanoparticles for drug delivery. J. Control. Release 166:2 (2013), 182–194.
    • (2013) J. Control. Release , vol.166 , Issue.2 , pp. 182-194
    • Naahidi, S.1    Jafari, M.2    Edalat, F.3
  • 27
    • 84890924596 scopus 로고    scopus 로고
    • Advances in nanoparticulate carriers for oral delivery of peptides and proteins: polymeric vs. lipid nanoparticles
    • American Scientific Publishers
    • [27] Silva, A., Santos, D., Ferreira, D., et al. Advances in nanoparticulate carriers for oral delivery of peptides and proteins: polymeric vs. lipid nanoparticles. Encyclopedia of Nanoscience and Nanotechnology, 2011, American Scientific Publishers, 133–146.
    • (2011) Encyclopedia of Nanoscience and Nanotechnology , pp. 133-146
    • Silva, A.1    Santos, D.2    Ferreira, D.3
  • 28
    • 84960201366 scopus 로고    scopus 로고
    • PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
    • [28] Suk, J.S., Xu, Q., Kim, N., et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99 (2016), 28–51.
    • (2016) Adv. Drug Deliv. Rev. , vol.99 , pp. 28-51
    • Suk, J.S.1    Xu, Q.2    Kim, N.3
  • 29
    • 43249095490 scopus 로고    scopus 로고
    • A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization
    • [29] Craparo, E.F., Pitarresi, G., Bondì, M.L., et al. A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization. Macromol. Biosci. 8:3 (2008), 247–259.
    • (2008) Macromol. Biosci. , vol.8 , Issue.3 , pp. 247-259
    • Craparo, E.F.1    Pitarresi, G.2    Bondì, M.L.3
  • 30
    • 84936972869 scopus 로고    scopus 로고
    • Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases
    • [30] Fornaguera, C., Feiner-Gracia, N., Calderó, G., et al. Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases. Nanoscale 7:28 (2015), 12076–12084.
    • (2015) Nanoscale , vol.7 , Issue.28 , pp. 12076-12084
    • Fornaguera, C.1    Feiner-Gracia, N.2    Calderó, G.3
  • 31
    • 78149410923 scopus 로고    scopus 로고
    • Formation of polymeric nano-emulsions by a low-energy method and their use for nanoparticle preparation
    • [31] Calderó, G., García-Celma, M.J., Solans, C., Formation of polymeric nano-emulsions by a low-energy method and their use for nanoparticle preparation. J. Colloid Interface Sci. 353:2 (2011), 406–411.
    • (2011) J. Colloid Interface Sci. , vol.353 , Issue.2 , pp. 406-411
    • Calderó, G.1    García-Celma, M.J.2    Solans, C.3
  • 32
    • 84898997453 scopus 로고    scopus 로고
    • Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation
    • [32] Md, S., Ali, M., Ali, R., et al. Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation. Int. J. Biol. Macromol. 67 (2014), 418–425.
    • (2014) Int. J. Biol. Macromol. , vol.67 , pp. 418-425
    • Md, S.1    Ali, M.2    Ali, R.3
  • 33
    • 84893271973 scopus 로고    scopus 로고
    • Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting
    • [33] Bhavna, Md, S., Ali, M., et al. Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev. Ind. Pharm. 40:2 (2014), 278–287.
    • (2014) Drug Dev. Ind. Pharm. , vol.40 , Issue.2 , pp. 278-287
    • Bhavna1    Md, S.2    Ali, M.3
  • 34
    • 85010071837 scopus 로고    scopus 로고
    • Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro
    • (Vienna, Austria: 1996)
    • [34] Baysal, I., Ucar, G., Gultekinoglu, M., et al. Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. J. Neural Transm., 2016 (Vienna, Austria: 1996).
    • (2016) J. Neural Transm.
    • Baysal, I.1    Ucar, G.2    Gultekinoglu, M.3
  • 35
    • 84949579969 scopus 로고    scopus 로고
    • Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain
    • [35] Hanafy, A.S., Farid, R.M., ElGamal, S.S., Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain. Drug Dev. Ind. Pharm. 41:12 (2015), 2055–2068.
    • (2015) Drug Dev. Ind. Pharm. , vol.41 , Issue.12 , pp. 2055-2068
    • Hanafy, A.S.1    Farid, R.M.2    ElGamal, S.S.3
  • 36
    • 84861115952 scopus 로고    scopus 로고
    • Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting
    • [36] Fazil, M., Md, S., Haque, S., et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur. J. Pharm. Sci. 47:1 (2012), 6–15.
    • (2012) Eur. J. Pharm. Sci. , vol.47 , Issue.1 , pp. 6-15
    • Fazil, M.1    Md, S.2    Haque, S.3
  • 37
    • 77957260011 scopus 로고    scopus 로고
    • Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies
    • [37] Joshi, S.A., Chavhan, S.S., Sawant, K.K., Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur. J. Pharm. Biopharm. 76:2 (2010), 189–199.
    • (2010) Eur. J. Pharm. Biopharm. , vol.76 , Issue.2 , pp. 189-199
    • Joshi, S.A.1    Chavhan, S.S.2    Sawant, K.K.3
  • 38
    • 84998654804 scopus 로고    scopus 로고
    • New-fangled approach in the management of Alzheimer by formulation of polysorbate 80 coated chitosan nanoparticles of rivastigmine for brain delivery and their in vivo evaluation
    • [38] Khemariya, R.P., Khemariya, P.S., New-fangled approach in the management of Alzheimer by formulation of polysorbate 80 coated chitosan nanoparticles of rivastigmine for brain delivery and their in vivo evaluation. International Journal of Current Research in Medical Sciences 2:2 (2016), 18–29.
    • (2016) International Journal of Current Research in Medical Sciences , vol.2 , Issue.2 , pp. 18-29
    • Khemariya, R.P.1    Khemariya, P.S.2
  • 39
    • 84975206140 scopus 로고    scopus 로고
    • Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations
    • [39] Misra, S., Chopra, K., Sinha, V., et al. Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv., 1–10, 2015.
    • (2015) Drug Deliv. , vol.1-10
    • Misra, S.1    Chopra, K.2    Sinha, V.3
  • 40
    • 84924939569 scopus 로고    scopus 로고
    • Solid lipid nanoparticles loaded with lipoyl–memantine codrug: preparation and characterization
    • [40] Laserra, S., Basit, A., Sozio, P., et al. Solid lipid nanoparticles loaded with lipoyl–memantine codrug: preparation and characterization. Int. J. Pharm. 485:1 (2015), 183–191.
    • (2015) Int. J. Pharm. , vol.485 , Issue.1 , pp. 183-191
    • Laserra, S.1    Basit, A.2    Sozio, P.3
  • 41
    • 84936995824 scopus 로고    scopus 로고
    • Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters
    • [41] Shah, B., Khunt, D., Bhatt, H., et al. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur. J. Pharm. Sci. 78 (2015), 54–66.
    • (2015) Eur. J. Pharm. Sci. , vol.78 , pp. 54-66
    • Shah, B.1    Khunt, D.2    Bhatt, H.3
  • 42
    • 84873053242 scopus 로고    scopus 로고
    • Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease
    • [42] Ismail, M.F., ElMeshad, A.N., Salem, N.A.-H., Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease. Int. J. Nanomedicine, 8, 2013, 393.
    • (2013) Int. J. Nanomedicine , vol.8 , pp. 393
    • Ismail, M.F.1    ElMeshad, A.N.2    Salem, N.A.-H.3
  • 43
    • 84955139262 scopus 로고    scopus 로고
    • Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil
    • [43] Al Asmari, A.K., Ullah, Z., Tariq, M., et al. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des. Devel. Ther, 10, 2016, 205.
    • (2016) Drug Des. Devel. Ther , vol.10 , pp. 205
    • Al Asmari, A.K.1    Ullah, Z.2    Tariq, M.3
  • 44
    • 84884206111 scopus 로고    scopus 로고
    • Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration
    • [44] Yang, Z.-Z., Zhang, Y.-Q., Wang, Z.-Z., et al. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int. J. Pharm. 452:1 (2013), 344–354.
    • (2013) Int. J. Pharm. , vol.452 , Issue.1 , pp. 344-354
    • Yang, Z.-Z.1    Zhang, Y.-Q.2    Wang, Z.-Z.3
  • 45
    • 84861158528 scopus 로고    scopus 로고
    • Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes
    • [45] Li, W., Zhou, Y., Zhao, N., et al. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ. Toxicol. Pharmacol. 34:2 (2012), 272–279.
    • (2012) Environ. Toxicol. Pharmacol. , vol.34 , Issue.2 , pp. 272-279
    • Li, W.1    Zhou, Y.2    Zhao, N.3
  • 46
    • 84888341127 scopus 로고    scopus 로고
    • Amyloid-binding aptamer conjugated curcumin–PLGA nanoparticle for potential use in Alzheimer's disease
    • [46] Mathew, A., Aravind, A., Brahatheeswaran, D., et al. Amyloid-binding aptamer conjugated curcumin–PLGA nanoparticle for potential use in Alzheimer's disease. BioNanoScience 2:2 (2012), 83–93.
    • (2012) BioNanoScience , vol.2 , Issue.2 , pp. 83-93
    • Mathew, A.1    Aravind, A.2    Brahatheeswaran, D.3
  • 48
  • 49
    • 84949556196 scopus 로고    scopus 로고
    • Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers
    • [49] El-Salamouni, N.S., Farid, R.M., El-Kamel, A.H., et al. Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Int. J. Pharm. 496:2 (2015), 976–983.
    • (2015) Int. J. Pharm. , vol.496 , Issue.2 , pp. 976-983
    • El-Salamouni, N.S.1    Farid, R.M.2    El-Kamel, A.H.3
  • 50
    • 65949093025 scopus 로고    scopus 로고
    • Ferulic acid-loaded lipid nanostructures as drug delivery systems for Alzheimer's disease: preparation, characterization and cytotoxicity studies
    • [50] Bondi, M., Montana, G., Craparo, E., et al. Ferulic acid-loaded lipid nanostructures as drug delivery systems for Alzheimer's disease: preparation, characterization and cytotoxicity studies. Curr. Nanosci. 5:1 (2009), 26–32.
    • (2009) Curr. Nanosci. , vol.5 , Issue.1 , pp. 26-32
    • Bondi, M.1    Montana, G.2    Craparo, E.3
  • 52
    • 84957552037 scopus 로고    scopus 로고
    • Antitumoral-lipid-based nanoparticles: a platform for future application in osteosarcoma therapy
    • [52] Gonzalez-Fernandez, Y., Imbuluzqueta, E., Patino-Garcia, A., et al. Antitumoral-lipid-based nanoparticles: a platform for future application in osteosarcoma therapy. Curr. Pharm. Des. 21:42 (2015), 6104–6124.
    • (2015) Curr. Pharm. Des. , vol.21 , Issue.42 , pp. 6104-6124
    • Gonzalez-Fernandez, Y.1    Imbuluzqueta, E.2    Patino-Garcia, A.3
  • 53
    • 37849010813 scopus 로고    scopus 로고
    • Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization
    • Feb
    • [53] Estella-Hermoso de Mendoza, A., Rayo, M., Mollinedo, F., et al. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization. Eur. J. Pharm. Biopharm. 68:2 (Feb 2008), 207–213.
    • (2008) Eur. J. Pharm. Biopharm. , vol.68 , Issue.2 , pp. 207-213
    • Estella-Hermoso de Mendoza, A.1    Rayo, M.2    Mollinedo, F.3
  • 54
    • 84896837155 scopus 로고    scopus 로고
    • Lecithin-based nanostructured gels for skin delivery: an update on state of art and recent applications
    • [54] Elnaggar, Y.S., El-Refaie, W.M., El-Massik, M.A., et al. Lecithin-based nanostructured gels for skin delivery: an update on state of art and recent applications. J. Control. Release 180 (2014), 10–24.
    • (2014) J. Control. Release , vol.180 , pp. 10-24
    • Elnaggar, Y.S.1    El-Refaie, W.M.2    El-Massik, M.A.3
  • 55
    • 84938741225 scopus 로고    scopus 로고
    • Novel self-assembled, gel-core hyaluosomes for non-invasive management of osteoarthritis: in vitro optimization, ex vivo and in vivo permeation
    • [55] El-Refaie, W.M., Elnaggar, Y.S., El-Massik, M.A., et al. Novel self-assembled, gel-core hyaluosomes for non-invasive management of osteoarthritis: in vitro optimization, ex vivo and in vivo permeation. Pharm. Res. 32 (2015), 2901–2911.
    • (2015) Pharm. Res. , vol.32 , pp. 2901-2911
    • El-Refaie, W.M.1    Elnaggar, Y.S.2    El-Massik, M.A.3
  • 56
    • 34447285025 scopus 로고    scopus 로고
    • Cationic transfersomes based topical genetic vaccine against hepatitis B
    • [56] Mahor, S., Rawat, A., Dubey, P.K., et al. Cationic transfersomes based topical genetic vaccine against hepatitis B. Int. J. Pharm. 340:1 (2007), 13–19.
    • (2007) Int. J. Pharm. , vol.340 , Issue.1 , pp. 13-19
    • Mahor, S.1    Rawat, A.2    Dubey, P.K.3
  • 57
    • 84879977264 scopus 로고    scopus 로고
    • Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation
    • [57] Freag, M.S., Elnaggar, Y.S., Abdallah, O.Y., Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation. Int. J. Nanomedicine 8 (2013), 2385–2397.
    • (2013) Int. J. Nanomedicine , vol.8 , pp. 2385-2397
    • Freag, M.S.1    Elnaggar, Y.S.2    Abdallah, O.Y.3
  • 58
    • 84866737577 scopus 로고    scopus 로고
    • Improvement of drug safety by the use of lipid-based nanocarriers
    • [58] Lim, S.B., Banerjee, A., Önyüksel, H., Improvement of drug safety by the use of lipid-based nanocarriers. J. Control. Release 163:1 (2012), 34–45.
    • (2012) J. Control. Release , vol.163 , Issue.1 , pp. 34-45
    • Lim, S.B.1    Banerjee, A.2    Önyüksel, H.3
  • 59
    • 14144250911 scopus 로고    scopus 로고
    • Recent advances with liposomes as pharmaceutical carriers
    • [59] Torchilin, V.P., Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4:2 (2005), 145–160.
    • (2005) Nat. Rev. Drug Discov. , vol.4 , Issue.2 , pp. 145-160
    • Torchilin, V.P.1
  • 60
    • 84861051659 scopus 로고    scopus 로고
    • Current trends in liposome research
    • Pharmaceutical Nanocarriers: Humana Press
    • [60] ElBayoumi, T.A., Torchilin, V.P., Current trends in liposome research. Liposomes: Methods and Protocols, vol. 1, 2010, Pharmaceutical Nanocarriers: Humana Press, 1–27.
    • (2010) Liposomes: Methods and Protocols , vol.1 , pp. 1-27
    • ElBayoumi, T.A.1    Torchilin, V.P.2
  • 61
    • 63149175757 scopus 로고    scopus 로고
    • Delivery of peptide and protein drugs over the blood–brain barrier
    • [61] Brasnjevic, I., Steinbusch, H.W., Schmitz, C., et al. Delivery of peptide and protein drugs over the blood–brain barrier. Prog. Neurobiol. 87:4 (2009), 212–251.
    • (2009) Prog. Neurobiol. , vol.87 , Issue.4 , pp. 212-251
    • Brasnjevic, I.1    Steinbusch, H.W.2    Schmitz, C.3
  • 63
    • 84861311174 scopus 로고    scopus 로고
    • Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease)
    • [63] Spuch, C., Navarro, C., Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease). Journal of Drug Delivery, 2011, 2011.
    • (2011) Journal of Drug Delivery , vol.2011
    • Spuch, C.1    Navarro, C.2
  • 64
    • 31044441421 scopus 로고    scopus 로고
    • Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease
    • [64] Stefanova, E., Wall, A., Almkvist, O., et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J. Neural Transm. 113:2 (2006), 205–218.
    • (2006) J. Neural Transm. , vol.113 , Issue.2 , pp. 205-218
    • Stefanova, E.1    Wall, A.2    Almkvist, O.3
  • 65
    • 84887922844 scopus 로고    scopus 로고
    • Targeted drug delivery across the blood brain barrier in Alzheimer's disease
    • [65] Rocha, S., Targeted drug delivery across the blood brain barrier in Alzheimer's disease. Curr. Pharm. Des. 19:37 (2013), 6635–6646.
    • (2013) Curr. Pharm. Des. , vol.19 , Issue.37 , pp. 6635-6646
    • Rocha, S.1
  • 66
    • 84857543329 scopus 로고    scopus 로고
    • Nanotechnologies: a strategy to overcome blood–brain barrier
    • [66] De Rosa, G., Salzano, G., Caraglia, M., et al. Nanotechnologies: a strategy to overcome blood–brain barrier. Curr. Drug Metab. 13:1 (2012), 61–69.
    • (2012) Curr. Drug Metab. , vol.13 , Issue.1 , pp. 61-69
    • De Rosa, G.1    Salzano, G.2    Caraglia, M.3
  • 67
    • 84928128382 scopus 로고    scopus 로고
    • Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures
    • [67] Murugan, K., Choonara, Y.E., Kumar, P., et al. Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures. Int. J. Nanomedicine, 10, 2015, 2191.
    • (2015) Int. J. Nanomedicine , vol.10 , pp. 2191
    • Murugan, K.1    Choonara, Y.E.2    Kumar, P.3
  • 68
    • 84907508928 scopus 로고    scopus 로고
    • Designing the future of nanomedicine: current barriers to targeted brain therapeutics
    • [68] Herda, L.M., Polo, E., Kelly, P.M., et al. Designing the future of nanomedicine: current barriers to targeted brain therapeutics. Eur. J. Nanomed. 6:3 (2014), 127–139.
    • (2014) Eur. J. Nanomed. , vol.6 , Issue.3 , pp. 127-139
    • Herda, L.M.1    Polo, E.2    Kelly, P.M.3
  • 69
    • 82755182780 scopus 로고    scopus 로고
    • In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma
    • [69] Estella-Hermoso de Mendoza, A., Preat, V., Mollinedo, F., et al. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J. Control. Release 156:3 (2011), 421–426.
    • (2011) J. Control. Release , vol.156 , Issue.3 , pp. 421-426
    • Estella-Hermoso de Mendoza, A.1    Preat, V.2    Mollinedo, F.3
  • 71
    • 84899518848 scopus 로고    scopus 로고
    • Multifunctional nanoliposomes with curcumin–lipid derivative and brain targeting functionality with potential applications for Alzheimer disease
    • [71] Mourtas, S., Lazar, A.N., Markoutsa, E., et al. Multifunctional nanoliposomes with curcumin–lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur. J. Med. Chem. 80 (2014), 175–183.
    • (2014) Eur. J. Med. Chem. , vol.80 , pp. 175-183
    • Mourtas, S.1    Lazar, A.N.2    Markoutsa, E.3
  • 72
    • 84878024482 scopus 로고    scopus 로고
    • Functionalization with TAT-peptide enhances blood–brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-Î peptide
    • [72] Sancini, G., Gregori, M., Salvati, E., et al. Functionalization with TAT-peptide enhances blood–brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-Î peptide. J. Nanomed. Nanotechnol., 2013, 2013.
    • (2013) J. Nanomed. Nanotechnol. , vol.2013
    • Sancini, G.1    Gregori, M.2    Salvati, E.3
  • 73
    • 84899523576 scopus 로고    scopus 로고
    • Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies
    • [73] Markoutsa, E., Papadia, K., Giannou, A., et al. Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies. Pharm. Res. 31:5 (2014), 1275–1289.
    • (2014) Pharm. Res. , vol.31 , Issue.5 , pp. 1275-1289
    • Markoutsa, E.1    Papadia, K.2    Giannou, A.3
  • 74
    • 84957078663 scopus 로고    scopus 로고
    • The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: potential therapeutic approach for Alzheimer disease
    • [74] Mancini, S., Minniti, S., Gregori, M., et al. The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: potential therapeutic approach for Alzheimer disease. Nanomedicine: Nanotechnology, Biology and Medicine 12:1 (2016), 43–52.
    • (2016) Nanomedicine: Nanotechnology, Biology and Medicine , vol.12 , Issue.1 , pp. 43-52
    • Mancini, S.1    Minniti, S.2    Gregori, M.3
  • 75
    • 41849118077 scopus 로고    scopus 로고
    • The properties of liposomes produced from milk fat globule membrane material using different techniques
    • [75] Thompson, A.K., Mozafari, M.R., Singh, H., The properties of liposomes produced from milk fat globule membrane material using different techniques. Lait 87:4–5 (2007), 349–360.
    • (2007) Lait , vol.87 , Issue.4-5 , pp. 349-360
    • Thompson, A.K.1    Mozafari, M.R.2    Singh, H.3
  • 76
    • 79953685905 scopus 로고    scopus 로고
    • Nanonization strategies for poorly water-soluble drugs
    • [76] Chen, H., Khemtong, C., Yang, X., et al. Nanonization strategies for poorly water-soluble drugs. Drug Discov. Today 16:7 (2011), 354–360.
    • (2011) Drug Discov. Today , vol.16 , Issue.7 , pp. 354-360
    • Chen, H.1    Khemtong, C.2    Yang, X.3
  • 77
    • 85028127551 scopus 로고    scopus 로고
    • Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
    • [77] Lu, Y., Park, K., Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm. 453:1 (2013), 198–214.
    • (2013) Int. J. Pharm. , vol.453 , Issue.1 , pp. 198-214
    • Lu, Y.1    Park, K.2
  • 78
    • 84865758788 scopus 로고    scopus 로고
    • Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: peroral and mucosal routes
    • [78] Silva, A.C., Santos, D., Ferreira, D., et al. Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: peroral and mucosal routes. Curr. Med. Chem. 19:26 (2012), 4495–4510.
    • (2012) Curr. Med. Chem. , vol.19 , Issue.26 , pp. 4495-4510
    • Silva, A.C.1    Santos, D.2    Ferreira, D.3
  • 79
    • 84885227307 scopus 로고    scopus 로고
    • Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment
    • [79] Sood, S., Jain, K., Gowthamarajan, K., Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids Surf. B: Biointerfaces 113 (2014), 330–337.
    • (2014) Colloids Surf. B: Biointerfaces , vol.113 , pp. 330-337
    • Sood, S.1    Jain, K.2    Gowthamarajan, K.3
  • 80
    • 85015635203 scopus 로고    scopus 로고
    • Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery
    • [80] Nasr, M., Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery. Drug Deliv., 1–9, 2015.
    • (2015) Drug Deliv. , vol.1-9
    • Nasr, M.1
  • 81
    • 84957899809 scopus 로고    scopus 로고
    • Nanoemulsions loaded Carbopol® 934 based gel for intranasal delivery of neuroprotective Centella asiatica extract: in-vitro and ex-vivo permeation study
    • [81] Jaiswal, M., Kumar, A., Sharma, S., Nanoemulsions loaded Carbopol® 934 based gel for intranasal delivery of neuroprotective Centella asiatica extract: in-vitro and ex-vivo permeation study. J. Pharm. Investig. 46:1 (2016), 79–89.
    • (2016) J. Pharm. Investig. , vol.46 , Issue.1 , pp. 79-89
    • Jaiswal, M.1    Kumar, A.2    Sharma, S.3
  • 82
    • 84890345966 scopus 로고    scopus 로고
    • A critical appraisal of microemulsions for drug delivery: part I
    • [82] Sapra, B., Thatai, P., Bhandari, S., et al. A critical appraisal of microemulsions for drug delivery: part I. Ther. Deliv. 4:12 (2013), 1547–1564.
    • (2013) Ther. Deliv. , vol.4 , Issue.12 , pp. 1547-1564
    • Sapra, B.1    Thatai, P.2    Bhandari, S.3
  • 83
    • 84870248465 scopus 로고    scopus 로고
    • Microemulsion-based media as novel drug delivery systems
    • [83] Lawrence, M.J., Rees, G.D., Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 64 (2012), 175–193.
    • (2012) Adv. Drug Deliv. Rev. , vol.64 , pp. 175-193
    • Lawrence, M.J.1    Rees, G.D.2
  • 84
    • 84942892337 scopus 로고    scopus 로고
    • Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization
    • [84] Shah, B.M., Misra, M., Shishoo, C.J., et al. Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization. Drug Deliv. 22:7 (2015), 918–930.
    • (2015) Drug Deliv. , vol.22 , Issue.7 , pp. 918-930
    • Shah, B.M.1    Misra, M.2    Shishoo, C.J.3
  • 85
    • 84860358563 scopus 로고    scopus 로고
    • Microemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer's disease
    • [85] Shi, J., Cong, W., Wang, Y., et al. Microemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer's disease. Drug Dev. Ind. Pharm. 38:6 (2012), 752–761.
    • (2012) Drug Dev. Ind. Pharm. , vol.38 , Issue.6 , pp. 752-761
    • Shi, J.1    Cong, W.2    Wang, Y.3
  • 86
    • 0033119135 scopus 로고    scopus 로고
    • Dendrimers: from design to application—a progress report
    • [86] Fischer, M., Vögtle, F., Dendrimers: from design to application—a progress report. Angew. Chem. Int. Ed. 38:7 (1999), 884–905.
    • (1999) Angew. Chem. Int. Ed. , vol.38 , Issue.7 , pp. 884-905
    • Fischer, M.1    Vögtle, F.2
  • 87
    • 0003518691 scopus 로고    scopus 로고
    • Dendritic Molecules: Concepts, Syntheses, Perspectives
    • Wiley VCH
    • [87] Moorefield, C.N., Vögtle, F., Dendritic Molecules: Concepts, Syntheses, Perspectives. 2008, Wiley VCH.
    • (2008)
    • Moorefield, C.N.1    Vögtle, F.2
  • 88
    • 0021586266 scopus 로고
    • A new class of polymers: starburst-dendritic
    • [88] Tomalia, D., Baker, H., Dewald, J., et al. A new class of polymers: starburst-dendritic. Polym. J. 17:1 (1985), 117–132.
    • (1985) Polym. J. , vol.17 , Issue.1 , pp. 117-132
    • Tomalia, D.1    Baker, H.2    Dewald, J.3
  • 89
    • 81255152309 scopus 로고    scopus 로고
    • Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid–dendrimer aggregates morphology and cell toxicity
    • [89] Klementieva, O., Benseny-Cases, N., Gella, A., et al. Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid–dendrimer aggregates morphology and cell toxicity. Biomacromolecules 12:11 (2011), 3903–3909.
    • (2011) Biomacromolecules , vol.12 , Issue.11 , pp. 3903-3909
    • Klementieva, O.1    Benseny-Cases, N.2    Gella, A.3
  • 90
    • 84858060499 scopus 로고    scopus 로고
    • 1–28) peptide and MAP-Tau protein aggregation
    • 1–28) peptide and MAP-Tau protein aggregation. Mol. Pharm. 9:3 (2012), 458–469.
    • (2012) Mol. Pharm. , vol.9 , Issue.3 , pp. 458-469
    • Wasiak, T.1    Ionov, M.2    Nieznanski, K.3
  • 91
    • 84903185308 scopus 로고    scopus 로고
    • Research and development of anti-Alzheimer's drugs: an analysis based on technology flows measured by patent citations
    • [91] Xu, J., Kong, X., Qiu, L., et al. Research and development of anti-Alzheimer's drugs: an analysis based on technology flows measured by patent citations. Expert Opin. Ther. Pat. 24:7 (2014), 791–800.
    • (2014) Expert Opin. Ther. Pat. , vol.24 , Issue.7 , pp. 791-800
    • Xu, J.1    Kong, X.2    Qiu, L.3
  • 92
    • 84998817874 scopus 로고    scopus 로고
    • Dose-finding Study to Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
    • [March 3, 2016]; Available from:
    • [92] NCT02322021, Dose-finding Study to Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease. [March 3, 2016]; Available from: https://clinicaltrials.gov/ct2/show/NCT02322021, 2016.
    • (2016)
    • NCT023220211
  • 93
    • 84975840790 scopus 로고    scopus 로고
    • Anti-obesity effect of intranasal administration of galanin-like peptide (GALP) in obese mice
    • [93] Kageyama, H., Shiba, K., Hirako, S., et al. Anti-obesity effect of intranasal administration of galanin-like peptide (GALP) in obese mice. Sci. Rep., 6, 2016.
    • (2016) Sci. Rep. , vol.6
    • Kageyama, H.1    Shiba, K.2    Hirako, S.3
  • 94
    • 79961088853 scopus 로고    scopus 로고
    • Evaluation of the rabbit nasal cavity in inhalation studies and a comparison with other common laboratory species and man
    • [94] Pereira, M.E., Macri, N.P., Creasy, D.M., Evaluation of the rabbit nasal cavity in inhalation studies and a comparison with other common laboratory species and man. Toxicol. Pathol. 39:5 (2011), 893–900.
    • (2011) Toxicol. Pathol. , vol.39 , Issue.5 , pp. 893-900
    • Pereira, M.E.1    Macri, N.P.2    Creasy, D.M.3
  • 95
    • 84998756413 scopus 로고    scopus 로고
    • Galantamine, Donepezil, Rivastigmine and Memantine
    • [cited 2016 March 1]; Available from:
    • [95] Galantamine, Donepezil, Rivastigmine and Memantine. [cited 2016 March 1]; Available from: https://www.drugs.com/, 2016.
    • (2016)
  • 96
    • 84927686841 scopus 로고    scopus 로고
    • Nanoparticles for diagnosis and/or treatment of Alzheimer's disease
    • A. Tiwari John Wiley & Sons, Inc. New Jersy, USA
    • [96] Antimisiaris, S.G., Mourtas, S., Markoutsa, E., et al. Nanoparticles for diagnosis and/or treatment of Alzheimer's disease. Tiwari, A., (eds.) Advanced Healthcare Materials, 2014, John Wiley & Sons, Inc., New Jersy, USA, 87–179.
    • (2014) Advanced Healthcare Materials , pp. 87-179
    • Antimisiaris, S.G.1    Mourtas, S.2    Markoutsa, E.3
  • 97
    • 84871115007 scopus 로고    scopus 로고
    • Design and evaluation of chitosan nanoparticles as novel drug carriers for the delivery of donepezil
    • [97] Raja Azalea, D., Mohambed, M., Joji, S., et al. Design and evaluation of chitosan nanoparticles as novel drug carriers for the delivery of donepezil. Iranian Journal of Pharmaceutical Sciences 8:3 (2012), 155–164.
    • (2012) Iranian Journal of Pharmaceutical Sciences , vol.8 , Issue.3 , pp. 155-164
    • Raja Azalea, D.1    Mohambed, M.2    Joji, S.3
  • 98
    • 84860011902 scopus 로고    scopus 로고
    • Polymeric nanoparticles for drug delivery to the central nervous system
    • [98] Patel, T., Zhou, J., Piepmeier, J.M., et al. Polymeric nanoparticles for drug delivery to the central nervous system. Adv. Drug Deliv. Rev. 64:7 (2012), 701–705.
    • (2012) Adv. Drug Deliv. Rev. , vol.64 , Issue.7 , pp. 701-705
    • Patel, T.1    Zhou, J.2    Piepmeier, J.M.3
  • 100
    • 84873252557 scopus 로고    scopus 로고
    • Liposomal drug delivery systems: from concept to clinical applications
    • [100] Allen, T.M., Cullis, P.R., Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews 65:1 (2013), 36–48.
    • (2013) Advanced drug delivery reviews , vol.65 , Issue.1 , pp. 36-48
    • Allen, T.M.1    Cullis, P.R.2
  • 101
    • 24644519939 scopus 로고    scopus 로고
    • Engineering of nanoemulsions for drug delivery
    • [101] Sarker, D.K., Engineering of nanoemulsions for drug delivery. Current Drug Delivery 2:4 (2005), 297–310.
    • (2005) Current Drug Delivery , vol.2 , Issue.4 , pp. 297-310
    • Sarker, D.K.1
  • 102
    • 84883856935 scopus 로고    scopus 로고
    • Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases
    • [102] Bozdağ, P.S., Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm. Res. 30:10 (2013), 2499–2511.
    • (2013) Pharm. Res. , vol.30 , Issue.10 , pp. 2499-2511
    • Bozdağ, P.S.1
  • 105
    • 37649026816 scopus 로고    scopus 로고
    • Donepezil for dementia due to Alzheimer's disease
    • [105] Birks, J.H.R., Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst. Rev., 1, 2006, CD001190.
    • (2006) Cochrane Database Syst. Rev. , vol.1
    • Birks, J.H.R.1
  • 106
    • 33645510613 scopus 로고    scopus 로고
    • Galantamine for Alzheimer's disease and mild cognitive impairment
    • [106] Loy, C.S.L., Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. Rev., 1, 2006, CD001747.
    • (2006) Cochrane Database Syst. Rev. , vol.1
    • Loy, C.S.L.1
  • 107
    • 84998715754 scopus 로고    scopus 로고
    • Memantine Hydrochloride
    • [cited 2016 March 1]; Available from:
    • [107] European Medicines Agency, Memantine Hydrochloride. [cited 2016 March 1]; Available from: http://www.ema.europa.eu.
    • European Medicines Agency1
  • 108
    • 33947283745 scopus 로고    scopus 로고
    • Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease
    • [108] Jones, R.W., Bayer, A., Inglis, F., et al. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int. J. Geriatr. Psychiatry 22:3 (2007), 258–262.
    • (2007) Int. J. Geriatr. Psychiatry , vol.22 , Issue.3 , pp. 258-262
    • Jones, R.W.1    Bayer, A.2    Inglis, F.3
  • 109
    • 84877601800 scopus 로고    scopus 로고
    • Safety and efficacy of memantine extended-release in the management of Alzheimer's disease
    • [109] Corbett, A., Francis, P., Ballard, C., Safety and efficacy of memantine extended-release in the management of Alzheimer's disease. Clin. Med. Insights Ther. 5 (2013), 95–102.
    • (2013) Clin. Med. Insights Ther. , vol.5 , pp. 95-102
    • Corbett, A.1    Francis, P.2    Ballard, C.3
  • 111
    • 84879509747 scopus 로고    scopus 로고
    • Nanotechnology for CNS delivery of bio-therapeutic agents
    • [111] Amiji, LSSYM, Nanotechnology for CNS delivery of bio-therapeutic agents. Drug Deliv. Transl. Res. 3 (2013), 336–351.
    • (2013) Drug Deliv. Transl. Res. , vol.3 , pp. 336-351
    • Amiji1    LSSYM2
  • 112
    • 84938367332 scopus 로고    scopus 로고
    • Challenges and new strategies for therapeutic peptide delivery to the CNS
    • [112] McGowan, J.W., Bidwell, G.L. III, Vig, P.J., Challenges and new strategies for therapeutic peptide delivery to the CNS. Ther. Deliv. 6:7 (2015), 841–853.
    • (2015) Ther. Deliv. , vol.6 , Issue.7 , pp. 841-853
    • McGowan, J.W.1    Bidwell, G.L.2    Vig, P.J.3
  • 113
    • 69949165507 scopus 로고    scopus 로고
    • Commentary on “Alzheimer's disease drug development and the problem of the blood–brain barrier”
    • [113] S, J.W., Commentary on “Alzheimer's disease drug development and the problem of the blood–brain barrier”. Alzheimers Dement. 5:5 (2009), 433–434.
    • (2009) Alzheimers Dement. , vol.5 , Issue.5 , pp. 433-434
    • S, J.W.1
  • 114
    • 84999006812 scopus 로고    scopus 로고
    • Available from:
    • [114] ClinicalTrials.org, Available from: https://clinicaltrials.gov/, 2016.
    • (2016)
    • ClinicalTrials.org1
  • 116
    • 84895436939 scopus 로고    scopus 로고
    • Nanotoxicity overview: nano-threat to susceptible populations
    • [116] Li, Y., Zhang, Y., Yan, B., Nanotoxicity overview: nano-threat to susceptible populations. Int. J. Mol. Sci. 15:3 (2014), 3671–3697.
    • (2014) Int. J. Mol. Sci. , vol.15 , Issue.3 , pp. 3671-3697
    • Li, Y.1    Zhang, Y.2    Yan, B.3
  • 117
    • 84883856935 scopus 로고    scopus 로고
    • Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases
    • [117] Pehlivan, S.B., Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm. Res. 30 (2013), 2499–2511.
    • (2013) Pharm. Res. , vol.30 , pp. 2499-2511
    • Pehlivan, S.B.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.